Company Analysis
Sign in

Denali Therapeutics Inc. (DNLI)

Nasdaq: DNLI · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.7
◀ Past 5.7● Present 7.3▶ Future 4.1
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedFeb 26, 2026Feb 27, 2025Feb 28, 2024Feb 27, 2023Feb 28, 2022Feb 26, 2021Feb 27, 2020Mar 12, 2019Mar 19, 2018·
Revenue00330,531105,06548,657335,56126,320r129,100r00
Research and development418,778396,440423,876358,732265,353212,615193,382143,18374,46075,702
General and administrative136,564105,438103,35490,47579,05960,32646,48032,34915,68011,731
Total operating expenses555,342501,878527,230449,207344,412272,941239,862175,53290,14087,433
Operating income-555,342-487,341-196,699-340,744-295,75162,718-213,184-46,372-90,140-87,433
Total non-operating income (expense)··51,50514,7744,5959,24115,21910,1321,955781
Income tax expense102683021-575823r-35100·
Net income-512,540-422,773-145,224-325,991-290,58171,136-197,614-36,240-88,185-86,652
Earnings per share, basic-2.97-2.57-1.06-2.60-2.390.65-2.07-0.39··
Earnings per share, diluted-2.97-2.57-1.06-2.60-2.390.63-2.07-0.39··
Earnings per share, basic and diluted······-2.07-0.39-5.89-13.49
Weighted average shares, basic172,649,097164,473,772137,370,897125,530,703121,524,795108,974,13795,608,20892,621,991··
Weighted average shares, diluted172,649,097164,473,772137,370,897125,530,703121,524,795112,703,10895,608,20892,621,991··
Weighted average shares, basic and diluted······95,608,20892,621,99114,964,1446,424,720
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton DNLI · research, not advice